Jun 05, 2019 / 12:30PM GMT
Operator
Good morning. My name is Sherri, and I'll be your conference operator today. At this time, I would like to welcome everybody to Oncolytics Biotech conference call to discuss the codevelopment agreement with Pfizer and Merck KGaA. (Operator Instructions)
I will now turn the conference call over to your host, Michael Moore, Vice President, Investor Relations and Corporate Communications. Mr. Moore, please go ahead.
Michael Moore - Oncolytics Biotech Inc. - VP of IR & Corporate Communications
Thank you, Sherri. Good morning, ladies and gentlemen, and thank you for joining us on our call today to discuss this very important codevelopment agreement. With me on the call this morning from Oncolytics are Dr. Matt Coffey, President and Chief Executive Officer; Andrew de Guttadauro, President of Oncolytics Biotech U.S. and Global Head of Business Development; and Kirk Look, Chief Financial Officer.
On today's call, Dr. Coffey will discuss the codevelopment agreement announced this morning between Oncolytics and pharma partners Pfizer and Merck KGaA
Oncolytics Biotech Inc. - Shareholder/Analyst Call Transcript
Jun 05, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers